Journal of Chemistry

Journal of Chemistry / 2010 / Article

Open Access

Volume 7 |Article ID 259507 | 9 pages |

RP-HPLC Method for the Determination of Cinitapride in the Presence of its Degradation Products in Bulk Drug

Received28 Mar 2009
Accepted13 May 2009


A reverse phase HPLC method is described for the determination of cinitapride hydrogen tartrate in the presence of its degradation products in bulk drug. A drug was subjected to all stress conditions such as reduction, oxidation acidic and alkaline medium. Chromatography was recorded on an Intersil ODS-3 column using mixture of acetonitrile and phosphate buffer, pH adjusted to 6.7 in the ratio (70:30 v/v) as the mobile phase at the rate of 1.0 mL/min with detection at 260 nm. Glimepride was used as internal standard. The retention time of drug cinitapride was 3.8 min and glimepride an internal standard was 2.5 minute. The drug was found to degrade extensively in reduction conditions and mild degradation in the presence of in alkaline, acidic and oxidative but the drug was stable in thermal stress. The method was validated by determining its specificity, linearity, precision and accuracy. The developed method with good separation of all degradation products from drug could be successfully applied for the determination of cinitapride in the presence of its degradation products in the bulk drug. The proposed method is simple, fast, accurate and precise and hence applied for routine quality control of cinitapride in bulk drug. It can be used for analysis of samples during stability testing.

Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

480 Views | 1977 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.